Soluble ST2 may possess special superiority as a risk predictor in heart failure patients

International Journal of Cardiology

Volumn 186, Issue , 2015, Pages 146-147

  Zhou, Heng ^a   Ni, Jian ^a   Yuan, Yuan ^a   Deng, Wei ^a   Bian, Zhou Yan ^a   Tang, Qi Zhu ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Biomarkers; Heart failure; Prognosis; Soluble ST2

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATINE KINASE; INTERLEUKIN 1 RECEPTOR; PROTEIN ST2; UNCLASSIFIED DRUG; VALSARTAN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN;

APOPTOSIS; CARDIOVASCULAR RISK; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; LETTER; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; BLOOD; PROGNOSIS; RISK FACTOR;

BIOMARKERS; HEART FAILURE; HUMANS; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-1; RISK FACTORS;

EID: 84929175589     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.294     Document Type: Article

References (22)

1. A.M. Shah, and D.L. Mann In search of new therapeutic targets and strategies for heart failure: recent advances in basic science Lancet 378 9792 2011 704 712
2. A.L. Bui, T.B. Horwich, and G.C. Fonarow Epidemiology and risk profile of heart failure Nat. Rev. Cardiol. 8 1 2011 30 41
3. A. Gonzalez, S. Ravassa, and J. Beaumont New targets to treat the structural remodeling of the myocardium J. Am. Coll. Cardiol. 58 18 2011 1833 1843
4. G. Karayannis, F. Triposkiadis, and J. Skoularigis The emerging role of galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers Curr. Heart Fail. Rep. 10 4 2013 441 449
5. D. Schmitter, G. Cotter, and A.A. Voors Clinical use of novel biomarkers in heart failure: towards personalized medicine Heart Fail. Rev. 19 3 2014 369 381
6. E.O. Weinberg, M. Shimpo, and G.W. De Keulenaer Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction Circulation 106 23 2002 2961 2966
7. B. Dieplinger, and T. Mueller Soluble ST2 in heart failure Clin. Chim. Acta 443C 2014 57 70
8. M.M. Ciccone, F. Cortese, and M. Gesualdo A novel cardiac bio-marker: ST2: a review Molecules 18 12 2013 15314 15328
9. R. Kakkar, and R.T. Lee The IL-33/ST2 pathway: therapeutic target and novel biomarker Nat. Rev. Drug Discov. 7 10 2008 827 840
10. S. Sanada, D. Hakuno, and L.J. Higgins IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system J. Clin. Investig. 117 6 2007 1538 1549
11. K. Seki, S. Sanada, and A.Y. Kudinova Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling Circ. Heart Fail. 2 6 2009 684 691
12. E.O. Weinberg, M. Shimpo, and S. Hurwitz Identification of serum soluble ST2 receptor as a novel heart failure biomarker Circulation 107 5 2003 721 726
13. B. Ky, B. French, and K. McCloskey High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure Circ. Heart Fail. 4 2 2011 180 187
14. I.S. Anand, T.S. Rector, and M. Kuskowski Prognostic value of soluble ST2 in the valsartan heart failure trial Circ. Heart Fail. 7 3 2014 418 426
15. G.M. Felker, M. Fiuzat, and V. Thompson Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes Circ. Heart Fail. 6 6 2013 1172 1179
16. J.L. Januzzi Jr., W.F. Peacock, and A.S. Maisel Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study J. Am. Coll. Cardiol. 50 7 2007 607 613
17. D. Gruson, T. Lepoutre, and S.A. Ahn Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction Int. J. Cardiol. 172 1 2014 e250 e252
18. A. Bayes-Genis, M. de Antonio, and J. Vila Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3 J. Am. Coll. Cardiol. 63 2 2014 158 166
19. H.K. Gaggin, J. Szymonifka, and A. Bhardwaj Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure JACC Heart Fail. 2 1 2014 65 72
20. S.E. Piper, R.A. Sherwood, and G.F. Amin-Youssef Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure Int. J. Cardiol. 178 2015 284 291
21. H.K. Gaggin, S. Motiwala, and A. Bhardwaj Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure Circ. Heart Fail. 6 6 2013 1206 1213
22. A. Lax, J. Sanchez-Mas, and M.C. Asensio-Lopez Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction JACC Heart Fail. 3 1 2015 50 58